Cargando…
Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer
PURPOSE: We conducted an open-label, single-arm Phase I/II clinical trial in metastatic CRPC (mCRPC) patients eligible for docetaxel combined with treatment with autologous mature dendritic cells (DCs) pulsed with killed LNCaP prostate cancer cells (DCVAC/PCa). The primary and secondary endpoints we...
Autores principales: | Podrazil, Michal, Horvath, Rudolf, Becht, Etienne, Rozkova, Daniela, Bilkova, Pavla, Sochorova, Klara, Hromadkova, Hana, Kayserova, Jana, Vavrova, Katerina, Lastovicka, Jan, Vrabcova, Petra, Kubackova, Katerina, Gasova, Zdenka, Jarolim, Ladislav, Babjuk, Marek, Spisek, Radek, Bartunkova, Jirina, Fucikova, Jitka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627245/ https://www.ncbi.nlm.nih.gov/pubmed/26078335 |
Ejemplares similares
-
Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials
por: Fučíková, Jitka, et al.
Publicado: (2011) -
Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer
por: Beer, Tomasz M, et al.
Publicado: (2015) -
Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications
por: Fucikova, Jitka, et al.
Publicado: (2019) -
Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial
por: Rob, Lukas, et al.
Publicado: (2022) -
Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines
por: Hensler, Michal, et al.
Publicado: (2022)